Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anagrelide - Takeda

Next Previous
X
Search
Drug Profile

Anagrelide - Takeda

Alternative Names: Agrelid; Agrelin; Agrylin; Anagrelide hydrochloride; BL 4162A; BMY 2653801; KRN654; SPD422; Xagrid

Latest Information Update: 05 Nov 2023

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Takeda
  • Class 3-ring heterocyclic compounds; Antiplatelets; Antithrombotics; Imidazoles; Quinazolines; Small molecules
  • Mechanism of Action Fibrinolytic agents; Type 3 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thrombocytosis; Essential thrombocythaemia; Polycythaemia vera
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Thrombocytosis

Most Recent Events

  • 10 Apr 2019 Shire completes a phase I pharmacokinetics trial in healthy volunteers in USA (PO, Capsule) (NCT03866434)
  • 11 Mar 2019 NCT03866434: Added FET; CTP not created yet; brief review done
  • 07 Mar 2019 Shire plans a phase I pharmacokinetics trial in healthy volunteers in USA (PO, Capsule) (NCT03866434)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top